Last reviewed · How we verify
ATI-502
ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.
ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A. Used for Treatment of essential tremor.
At a glance
| Generic name | ATI-502 |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Drug class | Serotonin receptor antagonist |
| Target | 5-HT2A |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By blocking the 5-HT2A receptor, ATI-502 is thought to reduce excessive neural activity associated with various neurological disorders.
Approved indications
- Treatment of essential tremor
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) (PHASE2)
- A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATI-502 CI brief — competitive landscape report
- ATI-502 updates RSS · CI watch RSS
- Aclaris Therapeutics, Inc. portfolio CI